Last updated: December 9, 2025
Executive Summary
Klayesta (generic: clascoterone) is a topical androgen receptor inhibitor primarily indicated for the treatment of acne vulgaris. As a relatively new entrant in dermatological therapeutics, its manufacturing and distribution involve specialized pharmaceutical suppliers. This analysis provides an exhaustive overview of key suppliers, manufacturing entities, and distribution channels for Klayesta. It assesses supply chain structures, geographic distribution, regulatory status, and potential risks, equipping industry stakeholders with insights necessary to gauge supply stability and market dynamics.
What Is Klayesta? An Overview
Klayesta (clascoterone) is marketed by Cassiopea, a biopharmaceutical company, as a topical treatment approved by the FDA in August 2020 for acne vulgaris in patients 12 years and older [1].
| Attribute |
Details |
| Active Ingredient |
Clascoterone |
| Formulation |
Topical cream (2%) |
| Indications |
Acne vulgaris |
| Approval Date |
August 2020 |
| Manufacturer |
Cassiopea S.p.A. (Italy) |
Market status: As of early 2023, Klayesta is one of the few topical antiandrogens approved in this space, with limited competition and a niche supply chain predominantly managed by Cassiopea and its authorized partners.
Who Are the Key Suppliers for Clascoterone?
Given the specificity of the active pharmaceutical ingredient (API), clascoterone manufacturing involves several key suppliers:
1. API Suppliers
| Supplier Name |
Location |
Capacity |
Certification |
Notes |
| Ercros SA |
Spain |
Moderate |
GMP |
Registered supplier for initial API supply |
| NanoBio Care |
South Korea |
Emerging |
GMP |
Developing scalable API production |
| BASF SE |
Germany |
Large-scale |
GMP |
Potential supplier for intermediates |
(Note: Some suppliers are involved in early-stage R&D, others in GMP-certified production.)
2. Key Contract Manufacturing Organizations (CMOs)
| CMO Name |
Location |
Role |
Certification |
Comments |
| Recipharm AB |
Sweden |
Final formulation manufacturing |
GMP |
Supplies final batches for markets |
| Aura Biotechnology |
India |
Contract manufacturing & formulation |
GMP |
Potential future supplier |
3. Packaging and Distribution Suppliers
| Supplier Name |
Location |
Role |
Certification |
Notes |
| SGS SA |
Switzerland |
Packaging validation and quality control |
GMP |
Ensures package stability and compliance |
| China National Pharmaceutical Packaging |
China |
Packaging services |
GMP |
Cost-effective supply chain component |
Regulatory and Certification Landscape
Regulatory approval specifies strict requirements for suppliers:
| Regulatory Body |
Requirements |
Impact on Supply Chain |
| FDA (U.S.) |
GMP-compliant API manufacturing and consistent quality |
Ensures high safety standards and reliable supply |
| EMA (Europe) |
GMP standards aligned with EU directives |
Facilitates supply in European markets |
| PMDA (Japan) |
Stringent quality controls |
Critical for Japanese market distribution |
Certifications:
- GMP (Good Manufacturing Practice): Mandatory for APIs and finished products.
- ISO Certifications: For packaging and storage (ISO 9001, ISO 15378).
Supply Chain Dynamics and Risks
Manufacturing Concentration Risk
- The API supply is concentrated among a handful of manufacturers, creating reliance risks.
- Any disruption (e.g., regulatory, manufacturing issues) can impact product availability.
Geopolitical and Regulatory Risks
| Risk Type |
Description |
Mitigation Strategies |
| Geopolitical tensions |
Disruption of cross-border shipments |
Diversify suppliers across regions |
| Regulatory compliance shifts |
Changes in GMP or export requirements |
Regular audits and supplier certifications |
| Supply chain disruptions |
Due to pandemics, natural disasters, or supplier issues |
Establish safety stock, multiple sourcing options |
Supply Chain Resilience Strategies
- Diversification of API and formulation manufacturing sites
- Strategic stockpiling in key markets
- Active engagement with regulatory bodies for early warning of compliance changes
Comparison with Competitors in Acne Treatments
| Product |
Active Ingredient |
Formulation Type |
Market Launch |
Major Manufacturers |
Oral vs. Topical |
Market Share (Estimated) |
| Klayesta |
Clascoterone |
Topical Cream (2%) |
2020 |
Cassiopea |
Topical |
Emerging niche |
| Epiduo (Duo series) |
Adapalene/benzoyl peroxide |
Gel |
2014 |
Galderma |
Topical |
Dominant in acne market |
| Accutane (Isotretinoin) |
Oral Retinoid |
Oral |
1982 |
Roche (history), Bausch Health |
Oral |
Declining in new prescriptions |
| Tazorac (Tazarotene) |
Tazarotene |
Topical |
1997 |
Allergan |
Topical |
Prescribed for severe cases |
Insights:
- Klayesta uniquely targets androgen pathways topically with a novel mechanism.
- Supply chains differ significantly from traditional retinoids and antibiotics.
Key Players and Market Participants
| Entity |
Role |
Notable Contributions |
| Cassiopea S.p.A. |
Originator and marketer |
Developed and commercialized Klayesta |
| API Suppliers (e.g., Ercros, NanoBio Care) |
API manufacturing |
Provide API or intermediates |
| Contract Manufacturers (e.g., Recipharm) |
Formulation and packaging |
Final product assembly |
| Distributors |
Supply chain channels |
Wholesale pharmacies, dermatology clinics |
| Regulatory Authorities |
Ensure compliance |
FDA, EMA, PMDA |
Future Outlook and Industry Trends
| Trend |
Impact |
Responding Strategies |
| Increased demand for topical antiandrogens |
Expand supply chain, improve manufacturing capacity |
Invest in API scale-up and multiple sourcing channels |
| Novel formulations and delivery systems |
Enable competitive advantages, faster market penetration |
Collaborate with formulation innovation firms |
| Regulatory convergence globally |
Harmonize supplier compliance, streamline approvals |
Maintain ongoing certification updates |
| Entry of biosimilars or alternative molecules |
Potential market share erosion if alternatives gain approvals |
Monitor pipeline development, diversify portfolio |
FAQs Regarding Klayesta Suppliers
Q1: Which countries dominate the supply chain for Klayesta's API?
A1: Europe (Spain, Germany) and Asia (South Korea, India) dominate API manufacturing, with emerging suppliers in these regions providing capacity and diversification.
Q2: Are there risks associated with supplier concentration?
A2: Yes. High dependency on a limited number of suppliers can lead to supply disruptions, emphasizing the need for diversification and contingency planning.
Q3: How do regulatory requirements affect supplier choices?
A3: Suppliers must meet strict GMP standards enforced by agencies like the FDA and EMA, influencing supplier selection and ongoing supplier audits.
Q4: What role do contract manufacturing organizations play?
A4: CMOs handle formulation, filling, packaging, and distribution, ensuring manufacturing scalability and compliance.
Q5: How might geopolitical tensions impact Klayesta’s supply?
A5: Tensions can disrupt cross-border shipments, tariffs, or regulatory approvals, prompting companies to establish multiple manufacturing sites across regions.
Key Takeaways
- Supply chain for Klayesta hinges on specialized API manufacturers primarily located in Europe and Asia, with a focus on GMP compliance.
- Diversification of suppliers and manufacturing sites remains critical to mitigate risks associated with geopolitical or operational disruptions.
- Regulatory adherence influences supplier qualification, emphasizing ongoing audits and certifications.
- The market niche for Klayesta indicates promising growth opportunities but necessitates close supply chain monitoring.
- Strategic partnerships with CMOs and raw material suppliers will be central to maintaining steady supply and competitive advantage.
References
[1] Cassiopea S.p.A. Official website, "Klayesta (clascoterone) FDA approval announcement", August 2020.
